AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32589866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 29
Study 32589970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD regimen
Number of subjects: 0
Study 32590049 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (EVENITY™)
Number of subjects: 0
Study 32590049 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study 32590049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32590049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin antibody
Number of subjects: 0
Study 32590747 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily on days 1 to 21 of a 28-day cycle
Number of subjects: 21
Study 32591313 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function analyzer 200 during extracorporeal membrane oxygenation
Number of subjects: 0
Study 32591373 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 8596
Study 32591373 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 8596
Study 32591894 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI with Edwards SAPIEN 3 prosthesis
Number of subjects: 1745
Study 32591978 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib (100 mg) administered twice daily from Day 3 to Day 9, coadministered with methotrexate on Day 8
Number of subjects: 0
Study 32591978 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (15-25 mg)
Number of subjects: 0
Study 32592467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamorolone
Number of subjects: 39
Study 32592618 — intervention group
Group type: EXPERIMENTAL
Intervention: DeRidder Burst spinal cord stimulation (B-SCS)
Number of subjects: 0
Study 32592618 — intervention group
Group type: COMPARATOR
Intervention: NRS, PCS, EQ-5D, and eight-item Patient-Reported Outcomes Measurement Information System Physical Function
Number of subjects: 0
Study 32593288 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic group (S group)
Number of subjects: 71
Study 32593288 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 71
Study 32593297 — intervention group
Group type: EXPERIMENTAL
Intervention: ccNexFin monitor
Number of subjects: 23
Study 32593522 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of total polyphenols intake (319.9 mg/d)
Number of subjects: 2231
Study 32593522 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of flavonoids intake
Number of subjects: 2231
Study 32593522 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of total polyphenols intake
Number of subjects: 2231
Study 32593547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase 0.001 to 0.1 mg/kg weekly for 8 weeks, then adjusted to achieve blood Phe concentrations of 60 to 600 μmol/L in PAL-002.
Number of subjects: 40
Study 32593547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase 0.001 to 0.4 mg/kg 5 days/week for 13 weeks in PAL-004.
Number of subjects: 40
Study 32593675 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with metabolic syndrome (MS)
Number of subjects: 291
Study 32593675 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with high blood pressure
Number of subjects: 291
Study 32593675 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with increased triglycerides
Number of subjects: 291
Study 32593698 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 434
Study 32593698 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 434
Study 32593698 — intervention group
Group type: COMPARATOR
Intervention: Low CFR in men
Number of subjects: 434
Study 32593698 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR
Number of subjects: 434
Study 32594200 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural flushing with crystalloids after oxaliplatin-based HIPEC
Number of subjects: 10
Study 32594200 — intervention group
Group type: COMPARATOR
Intervention: No flushing after oxaliplatin-based HIPEC (Control)
Number of subjects: 10
Study 32594297 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac patients
Number of subjects: 45
Study 32594297 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 45
Study 32594377 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida antigen immunotherapy
Number of subjects: 44
Study 32595176 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN left atrial appendage closure (LAAC) device
Number of subjects: 54
Study 32595210 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori seropositivity
Number of subjects: 74
Study 32595210 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA seropositivity
Number of subjects: 74
Study 32595586 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic intervention
Number of subjects: 0
Study 32595586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32595593 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Timed Up and Go Test
Number of subjects: 0
Study 32595770 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) at a dosage of 0.469 mg/kg/week for 12 months (group A)
Number of subjects: 54
Study 32595770 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) for 6 months after 6 months untreated (group B)
Number of subjects: 54
Study 32595879 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week cognitive stimulation program
Number of subjects: 122
Study 32595879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study 32595918 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270
Study 32595918 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270
Study 32595918 — intervention group
Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (placebo group)
Number of subjects: 270
Study 32595978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 12
Study 32596803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic transperineal ultrasound (DTU)
Number of subjects: 34
Study 32596842 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg every 3 weeks)
Number of subjects: 84
Study 32597029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly or less frequent)
Number of subjects: 216
Study 32597029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly)
Number of subjects: 216
Study 32597029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic rurioctocog alfa pegol (PK-tailored dose regimen)
Number of subjects: 216
Study 32597029 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall haemostatic efficacy
Number of subjects: 216
Study 32597029 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) measures
Number of subjects: 216
Study 32597419 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 32597419 — intervention group
Group type: COMPARATOR
Intervention: Standard of care radiotherapy ± chemotherapy
Number of subjects: 30
Study 32597739 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecure participants with overweight/obesity
Number of subjects: 56
Study 32597739 — intervention group
Group type: COMPARATOR
Intervention: Food secure participants with normal weight
Number of subjects: 56
Study 32598033 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 8
Study 32598033 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin medication
Number of subjects: 8
Study 32598257 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg plus mFOLFOX6
Number of subjects: 10
Study 32598257 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 20 mg plus mFOLFOX6
Number of subjects: 10
Study 32598257 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 10
Study 32598257 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor plus mFOLFOX6
Number of subjects: 10
Study 32599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate embolization
Number of subjects: 70
Study 32600160 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease group
Number of subjects: 131
Study 32600160 — intervention group
Group type: COMPARATOR
Intervention: Abdominal aortic aneurysm group
Number of subjects: 131
Study 32600261 — intervention group
Group type: EXPERIMENTAL
Intervention: tcensReg method for estimating population mean and variance from censored observations
Number of subjects: 0
Study 32600261 — intervention group
Group type: COMPARATOR
Intervention: Tobit regression
Number of subjects: 0
Study 32600261 — intervention group
Group type: COMPARATOR
Intervention: Single imputation
Number of subjects: 0
Study 32600369 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with Sapien 3
Number of subjects: 2000
Study 32600369 — intervention group
Group type: COMPARATOR
Intervention: SAVR with Perimount Magna Ease
Number of subjects: 2000
Study 32600373 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-coated PVC ETTs
Number of subjects: 0
Study 32600373 — intervention group
Group type: EXPERIMENTAL
Intervention: Noble-metal-coated PVC ETTs
Number of subjects: 0
Study 32600373 — intervention group
Group type: COMPARATOR
Intervention: Uncoated PVC ETTs
Number of subjects: 0
Study 32600374 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal imaging biomarkers (magnetic resonance imaging (MRI) and ultrasound (US))
Number of subjects: 500
Study 32600857 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention including fish oil intake (2g daily), dietary counselling, and unsupervised physical exercise twice weekly during the first three cycles of treatment
Number of subjects: 123
Study 32600857 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 123
Study 32601111 — intervention group
Group type: EXPERIMENTAL
Intervention: EA (Expériences Animées) programme using animated short movies and discussions about psychoactive substances and addictions.
Number of subjects: 10
Study 32601114 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab treatment
Number of subjects: 160
Study 32601169 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin standard dosing
Number of subjects: 0
Study 32601337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Number of subjects: 0
Study 32601378 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-based combinations
Number of subjects: 0
Study 32601850 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN LAAC
Number of subjects: 0
Study 32601850 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory thrombosis and hemostasis markers
Number of subjects: 0
Study 32602006 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney dysfunction upon admission (eGFR < 60 mL/min/1.73 m²)
Number of subjects: 758
Study 32602006 — intervention group
Group type: COMPARATOR
Intervention: eGFR > 60 mL/min/1.73 m²
Number of subjects: 758
Study 32602562 — intervention group
Group type: EXPERIMENTAL
Intervention: Online survey assessment of physical and mental well-being
Number of subjects: 253
Study 32602677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk zone posting
Number of subjects: 3667
Study 32602677 — intervention group
Group type: COMPARATOR
Intervention: Low-risk zone posting
Number of subjects: 3667
Study 32602677 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic HCWs
Number of subjects: 3667
Study 32602677 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic HCWs
Number of subjects: 3667
Study 32602677 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ prophylaxis
Number of subjects: 3667
Study 32603248 — intervention group
Group type: EXPERIMENTAL
Intervention: Venovenous extracorporeal membrane oxygenation (VV-ECMO)
Number of subjects: 64
Study 32603248 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 64
Study 32603426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with cyclosporine (CSP) and mycophenolate mofetil (MMF)
Number of subjects: 77
Study 32603847 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous-only access techniques
Number of subjects: 4781
Study 32603847 — intervention group
Group type: COMPARATOR
Intervention: Cutdown-only access techniques
Number of subjects: 4781
Study 32603847 — intervention group
Group type: COMPARATOR
Intervention: Combined access techniques
Number of subjects: 4781
Study 32603847 — intervention group
Group type: COMPARATOR
Intervention: TEVAR group
Number of subjects: 4781
Study 32603847 — intervention group
Group type: COMPARATOR
Intervention: EVAR group
Number of subjects: 4781
Study 32603847 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall LOS
Number of subjects: 4781
Study 32604132 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed, uninfected infants (HEU)
Number of subjects: 238
Study 32604132 — intervention group
Group type: COMPARATOR
Intervention: HIV-unexposed, uninfected infants
Number of subjects: 238
Study 32604962 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + MTX with GC (≤10 mg/day)
Number of subjects: 646
Study 32604962 — intervention group
Group type: COMPARATOR
Intervention: Abatacept + MTX without GC (no-GC)
Number of subjects: 646
Study 32604962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab + MTX with GC (≤10 mg/day)
Number of subjects: 646
Study 32604962 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab + MTX without GC (no-GC)
Number of subjects: 646
Study 32604962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (abatacept and adalimumab)
Number of subjects: 646
Study 32605050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-fractionated stereotactic radiation (HFSRT; 6 Gy × 5) plus pembrolizumab (100 or 200 mg, every 3 weeks) and bevacizumab (10 mg/kg, every 2 weeks)
Number of subjects: 14
Study 32605298 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 374
Study 32605298 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 374
Study 32605575 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 4989
Study 32605575 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1 combined with clinical variables
Number of subjects: 4989
Study 32605575 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 4989
Study 32605623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Wishes Project (3WP) implementation
Number of subjects: 85
Study 32605623 — intervention group
Group type: EXPERIMENTAL
Intervention: Local adaptations of 3WP
Number of subjects: 85
Study 32605623 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured nature of the program
Number of subjects: 85
Study 32605623 — intervention group
Group type: EXPERIMENTAL
Intervention: Team approach to care
Number of subjects: 85
Study 32605637 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRCD group
Number of subjects: 43
Study 32605637 — intervention group
Group type: COMPARATOR
Intervention: non-CTRCD group
Number of subjects: 43
Study 32605888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab before radical cystectomy
Number of subjects: 143
Study 32605888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all MRI sequences
Number of subjects: 143
Study 32606056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions
Number of subjects: 0
Study 32606056 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential risk factors
Number of subjects: 0
Study 32606066 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus-based recommendations for perioperative medication safety tailored to country income level
Number of subjects: 108
Study 32606066 — intervention group
Group type: EXPERIMENTAL
Intervention: Online surveys using RedCAP
Number of subjects: 108
Study 32606066 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interviews
Number of subjects: 108
Study 32606101 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolus Retriever with Interlinked Cages (ERIC)
Number of subjects: 1230
Study 32606101 — intervention group
Group type: COMPARATOR
Intervention: Standard Stent Retrievers (SRs)
Number of subjects: 1230
Study 32606573 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% (PRO-145)
Number of subjects: 178
Study 32606573 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 178
Study 32606580 — intervention group
Group type: EXPERIMENTAL
Intervention: VisuEvo (VSE)
Number of subjects: 72
Study 32606580 — intervention group
Group type: COMPARATOR
Intervention: Control (CTN)
Number of subjects: 72
Study 32606580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 72
Study 32606578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 or 0.5 mg
Number of subjects: 759
Study 32606578 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 759
Study 32606705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate three monthly (PP3M)
Number of subjects: 922
Study 32606705 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once monthly (PP1M)
Number of subjects: 922
Study 32606705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paliperidone extended release (paliperidone ER)
Number of subjects: 922
Study 32606705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-adherent patients)
Number of subjects: 922
Study 32606883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (induction and maintenance)
Number of subjects: 454
Study 32606883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (induction and maintenance)
Number of subjects: 454
Study 32606883 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab/Placebo (vedolizumab induction, placebo maintenance)
Number of subjects: 454
Study 32606899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (LICUS, 3MHz, 0.132W/cm, 18,720 Joules)
Number of subjects: 33
Study 32606899 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 32606899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (LICUS)
Number of subjects: 33
Study 32606903 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nalbuphine with 12.5 mg hyperbaric bupivacaine
Number of subjects: 90
Study 32606903 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg midazolam with 12.5 mg hyperbaric bupivacaine
Number of subjects: 90
Study 32606903 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg hyperbaric bupivacaine plus 0.5 mL saline (Control)
Number of subjects: 90
Study 32606902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8% under heat conditions
Number of subjects: 12
Study 32606902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8% under exercise conditions
Number of subjects: 12
Study 32606902 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine topical system 1.8% under normal conditions
Number of subjects: 12
Study 32606902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8% under all conditions
Number of subjects: 12
Study 32606914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%
Number of subjects: 110
Study 32606914 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine patch 5%
Number of subjects: 110
Study 32606956 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg 3 times per day)
Number of subjects: 124
Study 32606956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (125 mg 3 times per day)
Number of subjects: 124
Study 32607095 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived natural products
Number of subjects: 0
Study 32607502 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered behavioral intervention for ART adherence and substance use
Number of subjects: 60
Study 32607502 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (facilitating referral to a local substance use treatment clinic)
Number of subjects: 60
Study 32607502 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention
Number of subjects: 60
Study 32607720 — intervention group
Group type: EXPERIMENTAL
Intervention: Families who authorized organ donation
Number of subjects: 1651
Study 32607720 — intervention group
Group type: COMPARATOR
Intervention: Families who refused organ donation
Number of subjects: 1651
Study 32607929 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Segmentation Tool (SST) administered by physicians and nurses
Number of subjects: 0
Study 32607967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 42
Study 32607967 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam
Number of subjects: 42
Study 32607967 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 42
Study 32608505 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies (various types including integrative, humanistic, cognitive behavioural, and third-wave cognitive behavioural therapies)
Number of subjects: 5517
Study 32608505 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies (various types)
Number of subjects: 5517
Study 32608579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19 and anti-CD20 CAR-T cells
Number of subjects: 21
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: External uterine compression
Number of subjects: 944
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Uterine arterial embolisation
Number of subjects: 944
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Balloon tamponade (condom catheter)
Number of subjects: 944
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Balloon tamponade (latex balloon catheter)
Number of subjects: 944
Study 32609374 — intervention group
Group type: COMPARATOR
Intervention: Bakri balloon tamponade
Number of subjects: 944